In a year that saw a significant rise in the clinical pipeline of cannabis-derived therapeutics and the worldwide sales of Epidiolex soar, the 3^rd International Cannabinoid Derived Pharmaceuticals Summit is back to facilitate continued growth in this sector and set the tone for the next year of forecasted groundbreaking research.

Join this critical global forum which will again be uniting industry specialists from pharma, biotechs, academia and solution providers as we target the most pressing issues important to bringing the next generation of CDPs to market.